68Ga-Labeled bombesin studies in patients with gastrointestinal stromal tumors:: Comparison with 18F-FDG

被引:99
作者
Dimitrakopoulou-Strauss, Antonia
Hohenberger, Peter
Haberkorn, Uwe
Maecke, Helmut R.
Eisenhut, Michael
Strauss, Ludwig G.
机构
[1] German Canc Res Ctr, Clin Cooperat Unit Nucl Med, Med PET Grp Biol Imaging, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, Klinikum Mannheim, Div Surg Oncol & Thorac Surg, Heidelberg, Germany
[3] Heidelberg Univ, Dept Nucl Med, Heidelberg, Germany
[4] Univ Basel Hosp, Dept Radiol, Div Radiol Chem, CH-4031 Basel, Switzerland
[5] German Canc Res Ctr, Dept Radiopharmaceut Chem, D-6900 Heidelberg, Germany
关键词
Ga-68-bombesin; F-18-FDG; GIST; PET; kinetic modeling;
D O I
10.2967/jnumed.106.038091
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Dynamic PET studies with a Ga-68-bombesin analog, DOTA-PEG(2)-[D-Tyr (6), beta-Ala(11),Thi(13) Nle(14)] BN(6-14) amide (Ga-68-BZH(3); DOTA is 1,4,7,10-tetraazacyclododecane-N,N',N '',N'''-tetraacetic acid, and PEG is ethylene glycol [2-aminoethyl-carboxymethyl ether]), were performed on patients with gastrointestinal stromal tumors (GIST) to investigate the impact of complementary receptor scintigraphy on diagnosis and the potential of a radionuclide treatment. Furthermore, dynamic F-18-FDG studies were performed on the same patients. Methods: This study comprised 17 patients with GIST. All patients were scheduled for therapy with imatinib because of unresectable primary or recurrent GIST or because of metastatic disease. Dynamic PET scans using Ga-68-BZH(3) and F-18-FDG were obtained on 2 consecutive days. Multivariate analysis was used to evaluate the kinetic data. Standardized uptake values (SUVs) were calculated, and a compartmental model (2-tissue) and noncompartmental model were used for data evaluation of both tracers. Results: Fourteen of 17 patients (25/30 lesions) were positive for uptake on F-18-FDG imaging, whereas Ga-68-BZH(3) demonstrated an enhanced accumulation in 7 of 17 patients (8/30 lesions). Thirteen lesions were confirmed by histologic examination, and the remaining 17 were confirmed by follow-up. One recurrent tumor in the stomach could not be delineated on F-18-FDG imaging but showed enhanced Ga-68-BZH(3) uptake. The median SUV for Ga-68-BZH(3) was 3.3, in comparison with 7.9 for 18F-FDG. Best-subset analysis demonstrated that the global SUV (55-60 min after injection) for F-18-FDG was primarily dependent on k3, followed by k1. Multivariate analysis did not show a significant correlation between the kinetic parameters (kl-k4, fractional blood volume, and SUV) for F-18-FDG and bombesin. Conclusion: Ga-68-BZH(3) may be helpful for diagnostic reasons in a subgroup of patients with GIST, as in the case of negative F-18-FDG findings and suspicion of viable tumor tissue. The meaning of the enhanced Ga-68-BZH(3) uptake is open at the moment.
引用
收藏
页码:1245 / 1250
页数:6
相关论文
共 20 条
  • [1] Burger C, 1997, J NUCL MED, V38, P1818
  • [2] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
    Demetri, GD
    von Mehren, M
    Blanke, CD
    Van den Abbeele, AD
    Eisenberg, B
    Roberts, PJ
    Heinrich, MC
    Tuveson, DA
    Singer, S
    Janicek, M
    Fletcher, JA
    Silverman, SG
    Silberman, SL
    Capdeville, R
    Kiese, B
    Peng, B
    Dimitrijevic, S
    Druker, BJ
    Corless, C
    Fletcher, CDM
    Joensuu, H
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) : 472 - 480
  • [3] Dimitrakopoulou-Strauss A., 2003, World J Nucl Med, V4, P306, DOI DOI 10.1102/14
  • [4] Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using 68Ga-DOTATOC PET and comparison with 18F-FDG PET
    Dimitrakopoulou-Strauss, Antonia
    Georgoulias, Vassilios
    Eisenhut, Michael
    Herth, Felix
    Koukouraki, Sophia
    Maecke, Helmut R.
    Haberkorn, Uwe
    Strauss, Ludwig G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (07) : 823 - 830
  • [5] The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate
    Goerres, GW
    Stupp, R
    Barghouth, G
    Hany, TF
    Pestalozzi, B
    Dizendorf, E
    Schnyder, P
    Luthi, F
    von Schulthess, GK
    Leyvraz, S
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (02) : 153 - 162
  • [6] Henze M, 2005, J NUCL MED, V46, P763
  • [7] HIGASHI K, 1993, J NUCL MED, V34, P414
  • [8] Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy
    Koukouraki, S
    Strauss, LG
    Georgoulias, V
    Schuhmacher, J
    Haberkorn, U
    Karkavitsas, N
    Dimitrakopoulou-Strauss, A
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (04) : 460 - 466
  • [9] Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy
    Koukouraki, Sophia
    Strauss, Ludwig G.
    Georgoulias, Vassilios
    Eisenhut, Michael
    Haberkorn, Uwe
    Dimitrakopoulou-Strauss, Antonia
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (10) : 1115 - 1122
  • [10] A JAVA']JAVA environment for medical image data analysis: initial application for brain PET quantitation
    Mikolajczyk, K
    Szabatin, M
    Rudnicki, P
    Grodzki, M
    Burger, C
    [J]. MEDICAL INFORMATICS, 1998, 23 (03): : 207 - 214